First Quadrant’s Pacific Biosciences PACB Stock Holding History

First Quadrant’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,200	Closed	-$557K	–	412
2021 Q4	$557K	Hold	27,200	–	–	0.06%	235
2021 Q3	$695K	Hold	27,200	–	–	0.08%	210
2021 Q2	$951K	Hold	27,200	–	–	0.11%	171
2021 Q1	$906K	Hold	27,200	–	–	0.1%	175
2020 Q4	$706K	Buy	+27,200	New	+$462K	0.07%	196

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Quadrant's PACB Position: Q1 2022 in Review

First Quadrant sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 27,200 shares — an estimated $557K sold.

First Quadrant first reported a position in PACB in Q4 2020 and held it in 5 quarters. The position peaked at $951K in Q2 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

First Quadrant reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 27,200 Pacific Biosciences shares in Q1 2022, an estimated $557K.
First Quadrant first reported a position in Pacific Biosciences in Q4 2020 and held it in 5 quarters.
First Quadrant's Pacific Biosciences position peaked at $951K in Q2 2021.
250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.